My questions: Hey Axel, I have some questions regarding Shivom. I have been following your company for some time now. Your idea has a great motivation behind and I would love the adoption of it.

First of all, the cap of 75m$ seems to be fairly high. Is there a reason why you aim to raise this amount of resources?

Secondly, regarding the tech behind Shivom, I understand what issue the blockchain is trying to solve. Nonetheless I don‘t see much usage (Token Velocity is a weak argument in my opinion) and also not much of a reason to hold the Shivom for longterm. Could you elaborate on this issue?

Lastly, this project is trying to enter the medical industry, an industry that is known for maximizing profits by binding customers long term and which is backed by governmental institutions and regulators, etc. Your project is trying to reduce costs and offer transparency, so basically the opposite. I looked up the whole team and I see lack of people with enough experience handling these regularity affairs. Can you confidently say that Shivom will succeed with competitors such as http://humanlongevity.com being already established and on the market?

Looking forward to your answer.

Regards

His answer:
Hi, thank you for your feedback. You have some well though through questions; that is appreciated; let me try to address them. The cap is actually not high at all; it is rather modest. We are aiming to build a large global company, and to do it right we need a reasonable amount of investment. We are focusing on the precision medicine market, and other companies raised significantly more money in the first round. For example, here what other companies in the precision medicine space raised in their first round: Grail ($1.3billion); iCarbonX ($306 mio), Calico ($316 mio), Human Longevity ($300 mio). And those companies are just covering tiny niche markets, while we at Shivom have larger markets and services in focus!

Second, long-term sustainability is what cunts for us, so it makes total sense for token holders to keep them long-term. Shivom is seeking to build a powerful center of gravity that brings the rest of the ecosystem into its orbit. Our global genomics ecosystem will ultimately be totally self-sustained, but will increase in profitability, adoption, and value through collaboration and network effects. As more service providers enter the Shivom ecosystem, more and more services and products will be available to users via OmiX tokens. For many users, it may be beneficial to keep and accumulate tokens long-term to access an increasing number of services for decreasing costs. Here a list of some of the planned use cases:
Users (B2C)
•  Buy genome sequencing kits to get your genome sequenced
•  Get access to health/fitness apps from 3rd party providers
•  Buy health insurance
•  Redeem for health-related products (partner pharmacy or online shop)
•  Buy other ‘omics’ kits (e.g. get your metabolome, transcriptome, microbiome, or epigenome tested)
•  Obtain your ancestry or genealogy profile
•  Analyze information on your pharmacogenetic profile (which drugs work for you and which do not)
•  Get personalized lifestyle, diet, and nutraceuticals advice
•  Understand evidence-based information on susceptibility to diseases and associated therapies
Organization (B2B)
•  Sponsor sequencing projects
•  Access the genome database and analytics
•  Pay donors for data & participation in research studies
•  Upload sequences to the ecosystem
•  Obtain secure cloud storage space for Omics data
•  Support rare disease projects
•  Find participants for research studies
•  Optimize patient stratification in clinical trials
•  Add apps and services to the platform
•  Store your proprietary DNA sequences for tamper-proof IP protection
•  Optimize patient stratification in clinical trials
•  Add apps and services to the platform
•  Store your proprietary DNA sequences for tamper-proof IP protection
Third, yes we are aiming at revolutionizing the healthcare market. With our new business model we can attract many user/clients that are no longer willing to support classical models in the healthcare industry.
Now we have the chance for assimilating, analyzing, and integrating omic data, electronic medical records, data obtained with mHealth devices, and other data of billions of people. Everybody will benefit when people can focus on innovating rather than getting bogged down in territorial and jurisdictional issues. In this context I do not see companies such as Human Longevity as strong competitors. They are local, serving only a minority of US people; Shivom on the other hand is a global endeavor, targeting also emerging markets, where we will see huge changes in the healthcare systems over the next years. We have already several top-advisors on board that have the necessary experience in guiding us in case our core team is lacking a certain domain knowledge. We will list those Advisors soon on our website. In addition, we will hire many top experts in the field to cover all areas to be truly successful. We have already a broader experience from several verticals (genomics, Bio-IT, Business dev, blockchain, business strategy, healthcare, innovation, etc..). Also, we are building an innovation council that brings together top thinkers and business people from around the globe; you will have difficulties finding many companies worldwide with such a wide variety of expertise. Key is that we can get new knowledge into our company; also we are an open innovation hub, which means we will engage a global community of enthusiasts that can support us. Already we get daily new requests of people who want to get involved and who love the project. Lots of opportunities for the future.